Final results of a phase Ib/IIa study of phenoxodiol in hormone-refractory prostate cancer.

被引：0
|
作者：
Davies, R
Tulloch, A
Frydenberg, M
Kelly, G
机构：
[1] Sir Charles Gairdiner Hosp, Perth, WA, Australia
[2] St John God Hosp, Perth, WA, Australia
[3] Monash Med Ctr, Melbourne, Vic, Australia
[4] Marshall Edwards Inc, Sydney, NSW, Australia
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9123S / 9123S
页数：1
相关论文
共 50 条
  • [1] A phase II study of temozolomide in hormone-refractory prostate cancer
    van Brussel, JP
    Busstra, MB
    Lang, MS
    Catsburg, T
    Schröder, FH
    Mickisch, GH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) : 509 - 512
  • [2] Gemcitabine in hormone-refractory prostate cancer: A phase II study
    Reissigl, A
    Brenner, H
    Chaitchik, S
    Sola, C
    Stackl, W
    Janko, C
    Krejcy, K
    ANNALS OF ONCOLOGY, 1998, 9 : 64 - 64
  • [3] A phase II study of temozolomide in hormone-refractory prostate cancer
    Jérôme P. van Brussel
    Martijn B. Busstra
    Margreet S. Lang
    Tilly Catsburg
    Fritz H. Schröder
    Gerald H. Mickisch
    Cancer Chemotherapy and Pharmacology, 2000, 45 : 509 - 512
  • [4] Phase I trial of sargramostim and thalidomide for treatment of hormone-refractory prostate cancer.
    Lilly, M
    Rowsell, EH
    Gurrola, R
    Ruckle, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 429S - 429S
  • [5] Hormone-Refractory prostate cancer
    Rini B.I.
    Small E.J.
    Current Treatment Options in Oncology, 2002, 3 (5) : 437 - 446
  • [6] Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer
    Eklund, John
    Kozloff, Mark
    Vlamakis, Joy
    Starr, Alexander
    Mariott, Margaret
    Gallot, Lilia
    Jovanovic, Borko
    Schilder, Lawrence
    Robin, Erwin
    Pins, Michael
    Bergan, Raymond C.
    CANCER, 2006, 106 (11) : 2459 - 2465
  • [7] Hormone-refractory prostate cancer
    Alexandre, I.
    Rixe, O.
    ANNALES D UROLOGIE, 2007, 41 (02) : 47 - 55
  • [8] Phase II study of topotecan in metastatic hormone-refractory prostate cancer
    Hudes, GR
    Kosierowski, R
    Greenberg, R
    Ramsey, HE
    Fox, SC
    Ozols, RF
    McAleer, CA
    Giantonio, BJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 235 - 240
  • [9] Etoposide and estramustine in previously treated hormone-refractory prostate cancer.
    Pavese, I.
    Di Palma, M.
    Mazzoli, M.
    Burattini, E.
    Satta, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] A Phase IIa trial of weekly EP0906 in patients with hormone-refractory prostate cancer (HPRC).
    Hussain, A
    Dipaola, RS
    Baron, AD
    Higano, CS
    Tchekmediyan, NS
    Miller, JA
    Rothermel, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 397S - 397S
12345